Regeneron Pharmaceuticals Inc. (REGN) News

Regeneron Pharmaceuticals Inc. (REGN): $746.37

10.29 (+1.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 380

in industry

Filter REGN News Items

REGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

REGN News Highlights

  • REGN's 30 day story count now stands at 22.
  • Over the past 22 days, the trend for REGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • CTMX, AVDL and PD are the most mentioned tickers in articles about REGN.

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Dexcom Leads 5 Stocks Near Buy Points

Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals.

Yahoo | November 26, 2022

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock suggesting impending weakness.

In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company...

Yahoo | November 26, 2022

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

Yahoo | November 25, 2022

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

Yahoo | November 23, 2022

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

Yahoo | November 23, 2022

Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Yahoo | November 22, 2022

There's Reason For Concern Over Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price

It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or "P/E") ratio of...

Yahoo | November 22, 2022

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

Yahoo | November 18, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 28% CAGR over the last three years

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Yahoo | November 18, 2022

Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?

CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).

William White on InvestorPlace | November 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6979 seconds.